15 Feb 2024 • In the ALPHEUS trial, evaluating chronic coronary syndrome patients undergoing complex PCI, the use of ticagrelor did not reduce the rate of periprocedural MI and major myocardial injuries compared to clopidogrel.

Despite complex PCI patients having elevated rates of periprocedural and cardiovascular events, ticagrelor did not outperform clopidogrel in mitigating these risks. Bleeding risks were low and similar in both groups.

There does not appear to be a benefit of stronger platelet suppression with ticagrelor compared to clopidogrel among patients with complex stable CAD.

Source: JACC | Read full story